Intercare to sell Medisys Hypoguard range in UK:
This article was originally published in Clinica
Intercare is to have exclusive UK rights to Medisys' Hypoguard diabetes products, which include a range of meters and test strips for the measurement of blood sugar levels. Harrogate, UK-based Intercare estimates the UK market for these products at £105 million ($152 million), with a 20% annual growth rate. Diabetes affects over 150 million people worldwide, with over half of sufferers going undiagnosed, Intercare says.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.